Sanofi-Synthelabo’s Eloxatin for Postsurgical Treatment of Stage III Colon Cancer
November 5, 2004 by admin · Leave a Comment
On November 5, 2004 Sanofi-Synthelabo’s Eloxatin™ (oxaliplatin for injection) received US FDA approval for use in combination with conventional chemotherapy (5-flurouracil and leukovorin) for the postsurgical treatment of stage III colon cancer patients. According to the company, this is the first new chemotherapy approval for the adjuvant treatment of colon cancer in over a decade. [...]
Erbitux
February 13, 2004 by admin · Leave a Comment
On Feb 12, 2004, ImClone Systems Incorporated and Bristol-Myers Squibb Company announced that the FDA approved the Erbitux (cetuximab) Injection for use in combination with irinotecan in the treatment of certain colorectal cancer patients. Particularly, Erbitux has been approved for patients with Epidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancer who are refractory to [...]